Search

Your search keyword '"Mostafa, Mostafa Reda"' showing total 44 results
Start Over Author "Mostafa, Mostafa Reda"
44 results on '"Mostafa, Mostafa Reda"'

10. Safety and Efficacy of Cangrelor in Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis

Author

Mostafa, Mostafa Reda, primary, Eid, Mohamed Magdi, additional, Awad, Ahmed K., additional, Takla, Andrew, additional, Hassan, Abdul Rhman, additional, Katamesh, Basant E., additional, AlBarakat, Majd M., additional, Ziada, Abdul Rhman, additional, Mohamed, Sarah, additional, Al-Azizi, Karim M., additional, and Goldsweig, Andrew M., additional

Published
2023
Full Text
View/download PDF

14. Long-term Outcomes of Acute Myocardial Infarction in Pre-existing Coronary Artery Ectasia: A Systematic Review and Meta-Analysis

Author

Eid, Mohamed Magdi, primary, Mostafa, Mostafa Reda, additional, Alabdouh, Ahmad, additional, AbdelQadir, Yossef Hassan, additional, Mohamed, Sarah, additional, Abdelazeem, Basel, additional, Ismayl, Mahmoud, additional, Abusnina, Waiel, additional, Alweis, Richard, additional, Corteville, David C.M., additional, Balmer-Swain, Mallory, additional, Paul, Timir K., additional, and Mamas, Mamas A., additional

Published
2023
Full Text
View/download PDF

17. GENDER DISPARITIES IN THE OUTCOME OF CARDIOGENIC SHOCK. A SYSTEMATIC REVIEW AND META-ANALYSIS.

Author

Mostafa, Mostafa Reda, primary, Eid, Mohamed, additional, Abusnina, Waiel, additional, Abuelazm, Mohamed, additional, Hassan, Abdul Rhman, additional, Katamesh, Basant, additional, Mahmoud, Abdelrahman, additional, Al-Abdouh, Ahmad, additional, Renjithlal, Sarath Lal Mannumbeth, additional, Al Ali, Omar Tayseer, additional, and Aboeata, Ahmed Salah Ahmed, additional

Published
2023
Full Text
View/download PDF

23. An overview of third, fourth and sixth cranial nerve palsies in the setting of COVID-19: A case report and systematic review

Author

Meshref, Mostafa, primary, Shaheen, Nour, additional, Swed, Sarya, additional, Ibrahim, Mohamed, additional, Mostafa, Mostafa Reda, additional, Algazar, Mohamed Osman, additional, Dobs, Monica, additional, Elsayed, Sarah Ibrahim, additional, Amro, Yara, additional, Afsa, Ahmed, additional, and Morra, Mostafa Ebraheem, additional

Published
2022
Full Text
View/download PDF

24. Efficacy of Anterior Lateral Electrode Compared with Anterior Posterior Electrode in External Cardioversion of Atrial Fibrillation. A Meta-Analysis of Clinical Trials

Author

Motawea, Karam R., primary, Mostafa, Mostafa Reda, additional, Magdi, Mohamed, additional, Swed, Sarya, additional, Fathy, Hager, additional, Aboelenein, Merna, additional, Belal, Mohamed Mohamed, additional, Awad, Dina M., additional, Talat, Nesreen Elsayed, additional, Rozan, Samah S., additional, Ansari, Sana Afreen, additional, Shahid, Rameen, additional, Sbitli, Taher, additional, Eweis, Ramy, additional, Bamousa, Bdoor, additional, Aslam, Muaaz, additional, Tanas, Yousef, additional, Dean, Yomna E., additional, Hasan, Walaa, additional, and Aiash, Hani, additional

Published
2022
Full Text
View/download PDF

26. A Meta-analysis of the Use of Polypill for Secondary Prevention of Atherosclerotic Cardiovascular Disease

Author

Al-Abdouh, Ahmad, primary, Mhanna, Mohammed, additional, Jabri, Ahmad, additional, Ahmed, Taha, additional, Altibi, Ahmed M., additional, Ghanem, Fares, additional, Alhuneafat, Laith, additional, Mostafa, Mostafa Reda, additional, Abusnina, Waiel, additional, Dewaswala, Nakeya, additional, Bhopalwala, Huzefa, additional, Kundu, Amartya, additional, and Michos, Erin D., additional

Published
2022
Full Text
View/download PDF

29. Bone Mineral Density as a Predictor of Cardiovascular Disease in Women: A Real-World Retrospective Study

Author

Renjithlal, Sarath Lal Mannumbeth, primary, Magdi, Mohamed, additional, Mostafa, Mostafa Reda, additional, Renjith, Keerthi, additional, Pillai, Parvathi, additional, Syed, Musaib, additional, Mohamed, Sarah, additional, Zahid, Viqarunnisa, additional, Ritter, Nathan, additional, Al Ali, Omar, additional, Balmer-Swain, Mallory, additional, Makaryus, Amjad, additional, and Pillai, Nisha, additional

Published
2022
Full Text
View/download PDF

30. Outcomes of atherectomy in treating severely calcified coronary lesions in patients with reduced left ventricular ejection fraction: A systematic review and meta-analysis

Author

Abusnina, Waiel, primary, Mostafa, Mostafa Reda, additional, Al-Abdouh, Ahmad, additional, Radaideh, Qais, additional, Ismayl, Mahmoud, additional, Alam, Mahboob, additional, Shah, Jaffer, additional, Yousfi, Noraldeen El, additional, Paul, Timir K., additional, Ben-Dor, Itsik, additional, and Dahal, Khagendra, additional

Published
2022
Full Text
View/download PDF

31. Ticagrelor use in patients after percutaneous coronary intervention: one year follow up in a community hospital

Author

Mannumbeth Renjithlal, Sarath Lal, Magdi, Mohamed, Renjith, Keerthi, Mostafa, Mostafa Reda, Syed, Musaib, Shaukat, Fahd, Zahid, Viqarunnisa, and Ritter, Nathan

Subjects
Original Article
Abstract

Background: Current guidelines from American College of Cardiology (ACC) recommend ticagrelor over clopidogrel in patients with acute coronary syndrome. We have observed many patients being switched from ticagrelor to clopidogrel after percutaneous coronary intervention (PCI) in our hospital. Our goal is to evaluate the use rate of ticagrelor and categorize the reasons for non-use. Methods: We performed a retrospective data analysis of all patients who underwent PCI at Unity Hospital of Rochester, New York, from January 2019 to January 2020. A total of 330 patients underwent PCI for ACS over the year. After exclusions, 277 patients were enrolled in the analysis. Results: Of the 277 patients, 179 (65%) completed one year of ticagrelor therapy, and 98 (35%) stopped ticagrelor and transitioned to clopidogrel. The most common reason for switching from ticagrelor was dyspnea (42 patients), followed by cost concerns (41 patients). Conclusion: At our community hospital, completion of one-year use of ticagrelor post-PCI occurred in 65% of patients. The most common reasons for discontinuation are dyspnea and medication cost.

Published
2022

35. The WATCHMAN device and post-implantation anticoagulation management. A review of key studies and the risk of device-related thrombosis

Author

Magdi, Mohamed, Renjithal, Sarath Lal Mannumbeth, Mubasher, Mahmood, Mostafa, Mostafa Reda, lathwal, Yashdeep, Mukuntharaj, Pradeeksha, Mohamed, Sarah, Alweis, Richard, Tan, Bryan E-Xin, and Baibhav, Bipul

Subjects
cardiovascular diseases, Review Article
Abstract

Background: Ischemic stroke is a devastating complication of atrial fibrillation (Afib). Anticoagulation is the gold standard to prevent stroke and systemic embolization. However, many patients have a contraindication to oral anticoagulation. The WATCHMAN device, which closes the left atrial appendage, is non-inferior to warfarin to prevent embolic events in clinical trials. Post-procedural anticoagulation is needed to avoid device-related thrombosis. The use of anticoagulants after WATCHMAN implantation in patients with high bleeding risks has been a source of debate. Objective: This article summarizes the current evidence on anticoagulation following the implantation of the WATCHMAN device, focusing on patients who have an absolute contraindication to oral anticoagulation. Observation: The WATCHMAN device is efficacious and safe in preventing stroke and systemic embolization. Warfarin and aspirin are given for 45 days after implantation. If TEE at 45 days shows minimal residual peri-device flow (≤ 5mm) and no device-related thrombus, warfarin is stopped. This is followed by aspirin and clopidogrel for six months, then aspirin indefinitely. Antithrombotic therapy with aspirin and clopidogrel for six months followed by daily aspirin indefinitely may be feasible for patients with an absolute contraindication to OAC. DOACs are more convenient to use than warfarin, and limited evidence suggests that they are not inferior following implantation of the device. Conclusion: Following the WATCHMAN implantation, the most often utilized regimen is warfarin followed by antiplatelet treatment. In cases where there is a high risk of bleeding, antiplatelets alone may be sufficient. More research is needed to tailor the existing antithrombotic regimen to the needs of patients.

Published
2021

37. Saphenous vein harvesting techniques for coronary artery bypass grafting: a systematic review and meta-analysis

Author

Vuong, Nguyen Lam, primary, Elfaituri, Muhammed Khaled, additional, Eldoadoa, Mohammed, additional, Karimzadeh, Sedighe, additional, Mokhtar, Mohamed Ashraf, additional, Eid, Peter Samuel, additional, Nam, Nguyen Hai, additional, Mostafa, Mostafa Reda, additional, Radwan, Ibrahim, additional, Zaki, Marwa Mostafa Mohamed, additional, Al Khudari, Rawan, additional, Kassem, Mahmoud, additional, and Huy, Nguyen Tien, additional

Published
2021
Full Text
View/download PDF

40. Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta‐analysis

Author

Morra, Mostafa Ebraheem, primary, Van Thanh, Le, additional, Kamel, Mohamed Gomaa, additional, Ghazy, Ahmed Abdelmotaleb, additional, Altibi, Ahmed M.A., additional, Dat, Lu Minh, additional, Thy, Tran Ngoc Xuan, additional, Vuong, Nguyen Lam, additional, Mostafa, Mostafa Reda, additional, Ahmed, Sarah Ibrahim, additional, Elabd, Sahar Samy, additional, Fathima, Samreen, additional, Le Huy Vu, Tran, additional, Omrani, Ali S., additional, Memish, Ziad A., additional, Hirayama, Kenji, additional, and Huy, Nguyen Tien, additional

Published
2018
Full Text
View/download PDF

41. Checkpoint Inhibitor Colitis With Superimposed Clostridioides difficile Infection.

Author

Mohammad AW, Kusnik A, Mostafa MR, Tan J, and Strapko A

Abstract

Immune checkpoint inhibitors (ICI) are commonly used for various malignancies. A particular checkpoint inhibitor is the anti-PD-1 antibody pembrolizumab. Immune-mediated diarrhea and colitis (IMDC) is the most frequently observed immune-related adverse event (irAE) involving the gastrointestinal system. Although immune-mediated colitis precipitated by pembrolizumab is rarely life-threatening, it often necessitates a detailed diagnostic workup, including stool studies, imaging, and colonoscopy, to establish an accurate diagnosis. The coexistence of IMDC and Clostridioides difficile infection is not well understood, but patients undergoing pembrolizumab treatment have comparable risk factors to those who develop C. difficile infection. We report a case of a 76-year-old female with nonmetastatic non-small cell lung cancer who was diagnosed with IMDC responsive to steroid treatment but later developed worsening diarrhea leading to a diagnosis of checkpoint inhibitor colitis with superimposed C. difficile infection., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2023, Mohammad et al.)

Published
2023
Full Text
View/download PDF

42. ORGANIZING PNEUMONIA: AN UNUSUAL SEQUELA OF COVID-19 INFECTION.

Author

Rivera LC, Mohamed S, Salar T, Mostafa MR, Najim M, Malik MA, Renjithal SLM, and Magdi M

Abstract

Organizing pneumonia (OP) is a form of interstitial lung disease that develops in response to acute lung injury. SARS-CoV-2 causes a wide range of lung and extrapulmonary disease, but there are few data suggesting an association between COVID-19 and OP. We describe a patient with COVID-19 pneumonia who developed severe progressive OP with significant morbidity., Learning Points: COVID-19 pneumonia is one of the secondary causes of organizing pneumonia (OP).Early initiation of steroids in OP is associated with improvement in symptoms and prognosis.A prolonged course of steroids may be needed in COVID-induced OP., Competing Interests: Conflicts of Interests: The Authors declare that there are no competing interests., (© EFIM 2023.)

Published
2023
Full Text
View/download PDF

43. Ticagrelor use in patients after percutaneous coronary intervention: one year follow up in a community hospital.

Author

Mannumbeth Renjithlal SL, Magdi M, Renjith K, Mostafa MR, Syed M, Shaukat F, Zahid V, and Ritter N

Abstract

Background: Current guidelines from American College of Cardiology (ACC) recommend ticagrelor over clopidogrel in patients with acute coronary syndrome. We have observed many patients being switched from ticagrelor to clopidogrel after percutaneous coronary intervention (PCI) in our hospital. Our goal is to evaluate the use rate of ticagrelor and categorize the reasons for non-use., Methods: We performed a retrospective data analysis of all patients who underwent PCI at Unity Hospital of Rochester, New York, from January 2019 to January 2020. A total of 330 patients underwent PCI for ACS over the year. After exclusions, 277 patients were enrolled in the analysis., Results: Of the 277 patients, 179 (65%) completed one year of ticagrelor therapy, and 98 (35%) stopped ticagrelor and transitioned to clopidogrel. The most common reason for switching from ticagrelor was dyspnea (42 patients), followed by cost concerns (41 patients)., Conclusion: At our community hospital, completion of one-year use of ticagrelor post-PCI occurred in 65% of patients. The most common reasons for discontinuation are dyspnea and medication cost., Competing Interests: None., (AJCD Copyright © 2022.)

Published
2022

44. A systematic review and meta-analysis of the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction.

Author

Magdi M, Mostafa MR, Abusnina W, Al-Abdouh A, Doss R, Mohamed S, Ekpo CP, Alweis R, and Baibhav B

Abstract

Background: Heart failure with preserved ejection fraction is a complex clinical syndrome marked by different phenotypes and related comorbidities. Transthyretin amyloidosis is an underestimated phenotype. We aim to evaluate the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction., Methods: This meta-analysis was conducted according to PRISMA guidelines. A search strategy was designed to utilize PubMed/Medline, EMBASE, and Google scholar to locate studies whose primary objective was to analyze the prevalence of transthyretin amyloidosis in heart failure preserved ejection fraction., Results: Of 271 studies initially identified, 5 studies comprising 670 patients were included in the final analysis. The prevalence of transthyretin amyloidosis was 11%. Patients with transthyretin amyloid cardiomyopathy were more likely to be males (RR 1.38; 95% CI 1.09 to 1.75; P<0.01; I 2 =37%), and more likely to have low voltage criteria on ECG (RR 2.98; 95% CI 1.03 to 8.58; P=0.04; I 2 =75%) compared with transthyretin negative group. They also have higher SMD of age (SMD 0.73; 95% CI 0.48 to 0.97; P<0.01; I 2 =0%), and NT-proBNP (SMD 0.48; 95% CI 0.02 to 0.93; P=0.04; I 2 =36%) compared with transthyretin negative group. On reported echocardiogram, they have higher SMD of mass index (SMD 0.77; 95% CI 0.27 to 1.27; P<0.01; I 2 =65%), posterior wall thickness (SMD 0.92; 95% CI 0.62 to 1.21; P<0.01; I 2 =0%), and septal wall thickness (SMD 1.49; 95% CI 0.65 to 2.32; P<0.01; I 2 =87%) compared with transthyretin negative group., Conclusion: Transthyretin amyloidosis affects 11% of HFpEF patients. Therefore, screening HFpEF patients at risk of cardiac amyloidosis is warranted., Competing Interests: None., (AJCD Copyright © 2022.)

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results